AbbVie under pressure as schizophrenia drug fails two trials

AbbVie under pressure as schizophrenia drug fails two trials - Nasdaq

Shares of AbbVie (ABBV) are sliding on Monday after the company's drug candidate for schizophrenia failed to meet the key goal in two ...

AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials

(Bloomberg) -- AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed ...

AbbVie's closely watched schizophrenia drug fails two studies ...

AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, ...

AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails ...

Analysts expressed surprise at the failure in both studies. AbbVie had been testing the drug in the EMPOWER program for patients with ...

Trending: AbbVie Schizophrenia Drug Fails in Mid-Stage Studies · More in Markets · More in Stocks · Sponsor Center.

AbbVie's schizophrenia drug misses main goals of two trials

(Reuters) -AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, ...

Schizophrenia drug AbbVie picked up in $9 billion acquisition fails ...

AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the ...

AbbVie's $9B schizophrenia prospect flunks phase 2 trials

The drug candidate at the center of AbbVie's $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, ...

AbbVie's emraclidine did not meet endpoint in Phase 2 ...

AbbVie's (ABBV) two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophr.

AbbVie's disappointing schizophrenia drug trial bodes well for rival ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday ...

AbbVie's Emraclidine Fails to Reduce Schizophrenia Symptoms ...

Data from the Phase II EMPOWER trial demonstrated that as an oral monotherapy, AbbVie's emraclidine did not reduce Positive and Negative ...

On Wall Street, 'flat out' failure of AbbVie schizophrenia drug leaves ...

Shares of another developer, Neumora Therapeutics, bobbed following AbbVie's announcement. A trial of Neumora's muscarinic drug was halted this ...

AbbVie Provides Update on Phase 2 Results for Emraclidine in ...

In the EMPOWER trials, emraclidine was well-tolerated with a safety profile comparable to that observed in the Phase 1b trial. The most commonly ...

AbbVie under pressure as schizophrenia drug fails two trials - X.com

AbbVie under pressure as schizophrenia drug fails two trials $ABBV $BMY https://t.co/MHiyX1S6d7.

Leerink upgrades Bristol to Outperform after AbbVie schizophrenia ...

... fails two trialsLeerink sees AbbVie's trial results as ' ... AbbVie under pressure as schizophrenia drug fails two trials · Leerink ...

AbbVie's schizophrenia candidate fails in two phase 2 trials

With emraclidine now unlikely to reach the market, AbbVie will be hoping that Cerevel's other assets fare better. One asset, tapavadon, for ...

AbbVie declines after missing main goal in schizophrenia treatment ...

AbbVie (ABBV) shares dropped 11% premarket as late-stage trials for schizophrenia drug emraclidine did not meet primary endpoint.

AbbVie News Center - News

All news · November 11, 2024. AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia · October 28, 2024. AbbVie to Acquire Aliada Therapeutics ...

AbbVie (ABBV) Suffers After Schizophrenia Drug Trial Disappointm

Despite this setback, AbbVie (ABBV, Financial) is committed to analyzing the trial data to decide on the future of emraclidine. The situation ...

New Developments in the Treatment of Schizophrenia: An Expert ...

Many recent attempts at developing drugs with novel MOAs have failed ... Multiple clinical trials are under way to further assess efficacy for acute ...